论文部分内容阅读
原发性肺癌是常见的恶性肿瘤之一,发病率逐年上升,由于早期误诊率较高,大多数患者(约85％)在确诊时已属中晚期,丧失了根治性切除的机会,治疗效果较差。自1990年以来,我们运用中药“仁康胶囊”结合化疗治疗中晚期肺癌38例,并设立单纯化疗组进行对比观察,从中西医结合角度探讨中晚期肺癌的治疗规律。 资料和方法 1、临床资料:73例肺癌患者均符合以下3条标准:①病理或细胞学证实为原发性肺癌。②按1985年国际肺癌分期属Ⅱ,Ⅳ期肺癌。③2月内未作过化疗,放疗及其它抗癌治疗。随机分为仁康胶囊+化疗组(治疗组)和单纯化疗组(对照组)。治疗组共38例,男性35例,女性3例;年龄31-72岁,平均年龄51岁;其中鳞癌18例,腺癌9例,小细胞癌11例。对照组共35例,男性30例,女性5例;年龄36～68岁,平均年龄48岁;其中鳞癌20例,腺癌5例,小细胞癌10例。治疗前全组病人行为状态(karnofsky)评分均在50分以上。
Primary lung cancer is one of the common malignancies. The incidence rate increases year by year. Due to the high rate of misdiagnosis in the early stages, most patients (about 85%) are in the advanced stage at the time of diagnosis and have lost the chance of radical resection. Poor. Since 1990, we have used traditional Chinese medicine “Renkang Capsule” combined with chemotherapy to treat 38 cases of advanced lung cancer, and established a simple chemotherapy group to conduct comparative observations, from the perspective of integrated traditional Chinese and Western medicine to explore the treatment of lung cancer. Materials and Methods 1. Clinical data: 73 patients with lung cancer all met the following three criteria: 1 pathological or cytological confirmed primary lung cancer. 2 According to the 1985 International Lung Cancer Stage II, IV lung cancer. No chemotherapy, radiotherapy or other anti-cancer treatment was performed within 32 months. Randomly divided into Renkang capsule + chemotherapy group (treatment group) and chemotherapy alone group (control group). The treatment group consisted of 38 patients, 35 males and 3 females. The age ranged from 31 to 72 years and the average age was 51 years. Among them, 18 were squamous cell carcinoma, 9 were adenocarcinoma, and 11 were small cell carcinoma. In the control group, there were 35 patients, 30 males and 5 females; aged 36 to 68 years and mean age 48 years; 20 of them were squamous cell carcinoma, 5 adenocarcinoma, and 10 small cell carcinoma. Before the treatment, all groups of patients had a karnofsky score of 50 points or more.